文献速递眼底病与葡萄膜炎青光眼

抗VEGF治疗视网膜静脉阻塞性黄斑水肿后眼压相关事件:SCORE2报告16二次分析

Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

SCORE2随机临床试验的二次分析纳入312例基线未用降眼压药物的视网膜中央或半侧静脉阻塞性黄斑水肿患者,初始随机接受阿柏西普或贝伐珠单抗6次每月注射。至60个月,8.0%出现眼压较基线升高>10 mmHg,1.6%眼压>35 mmHg,各1.0%接受降眼压切口或激光手术;两种药物间无差异。结论支持抗VEGF治疗期间监测眼压至60个月。

要点

  • 抗VEGF治疗CRVO/HRVO黄斑水肿后60个月内眼压升高>10 mmHg累积发生率为0.13。
  • 眼压>35 mmHg的60个月累积发生率为0.02,阿柏西普与贝伐珠单抗间无差异。
  • 降眼压切口手术和激光手术各发生在1.0%的参与者中。

核心结论

  • 抗VEGF治疗CRVO或HRVO相关黄斑水肿后眼压相关事件发生率支持在治疗期间监测眼压至60个月。

研究设计与样本

  • SCORE2随机临床试验的二次分析,纳入312例基线未使用降眼压药物的CRVO或HRVO黄斑水肿患者。
  • 参与者初始随机接受6次每月阿柏西普或贝伐珠单抗玻璃体腔注射,第6个月时按方案再随机或转换治疗。

主要发现

  • 25例(8.0%)出现眼压较基线升高>10 mmHg,5例(1.6%)眼压>35 mmHg。
  • 60个月Kaplan-Meier累积发生率:眼压升高>10 mmHg为0.13(95%CI 0.08-0.19),眼压>35 mmHg为0.02(95%CI 0.01-0.06)。
  • 上述眼压相关事件在初始随机接受阿柏西普或贝伐珠单抗的参与者间无差异。
  • 3例(1.0%)接受降眼压切口手术,3例(1.0%)接受降眼压青光眼激光手术。

关键数值与推荐

  • 眼压升高>10 mmHg的60个月累积发生率为0.13(95%CI 0.08-0.19)。
  • 眼压>35 mmHg的60个月累积发生率为0.02(95%CI 0.01-0.06)。

临床怎么用

  • 对因CRVO或HRVO黄斑水肿接受抗VEGF治疗的眼睛,应监测眼压至60个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are used to treat a variety of posterior segment conditions, including some associated with glaucoma, such as macular edema due to central retinal vein occlusion (CRVO). Therefore, information regarding intraocular pressure (IOP)-related events associated with anti-VEGF therapies is important to help balance the risks and benefits over the course of therapy. OBJECTIVE: To investigate IOP-related events among participants in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2). DESIGN, SETTING, AND PARTICIPANTS: Secondary analysis of a randomized clinical trial that included 312 participants with macular edema secondary to CRVO or hemiretinal vein occlusion (HRVO) who were not taking IOP-lowering medications at baseline. First randomization occurred on September 14, 2014, and contained data through data freeze on April 1, 2020. Analysis took place from April 2020 through December 2020. INTERVENTIONS: Study participants were initially randomized to 6 monthly intravitreal injections of aflibercept or bevacizumab. At month 6, protocol-defined good responders were rerandomized to continued monthly or treat-and-extend dosing of their originally assigned study drug, and protocol-defined poor or marginal responders were switched to alternative treatment. After month 12, participants were treated as per investigator discretion. MAIN OUTCOMES AND MEASURES: Three different outcomes: (1) IOP elevation more than 10 mm Hg from baseline, (2) IOP to a level higher than 35 mm Hg, and (3) IOP-lowering incisional or laser surgery. RESULTS: Of the 312 participants meeting inclusion criteria (138 [44.2%] were female; mean [SD] age, 67.8 [12.1] years), 25 (8.0%) had IOP elevation more than 10 mm Hg over baseline through month 60, and 5 (1.6%) had IOP higher than 35 mm Hg. The 60-month Kaplan-Meier cumulative incidence of IOP elevation more than 10 mm Hg over baseline was 0.13 (95% CI, 0.08-0.19), and the 60-month Kaplan-Meier cumulative incidence of IOP higher than 35 mm Hg was 0.02 (95% CI, 0.01-0.06), and did not differ among participants initially randomly assigned to receive aflibercept or bevacizumab. Three participants (1.0%) underwent IOP-lowering incisional surgery, and 3 participants (1.0%) underwent IOP-lowering glaucoma laser surgery. CONCLUSIONS AND RELEVANCE: Intravitreal anti-VEGF injections are used to treat some conditions associated with glaucoma, such as macular edema due to CRVO, and the rates of IOP-related events in this trial support monitoring IOP in eyes treated with anti-VEGF therapy for macular edema associated with CRVO or HRVO for up to 60 months. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01969708.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Aref AA, Scott IU, VanVeldhuisen PC, et al. Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2021. PMID: 34709363. doi:10.1001/jamaophthalmol.2021.4395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。